Delhi HC Stays NPPA's 151-cr Recovery from AstraZeneca

What happened

The Delhi High Court stopped the National Pharmaceutical Pricing Authority from taking coercive action to recover over 151 crore from AstraZeneca Pharma India in an alleged drug overcharging case until January 11, the next hearing date.

Confirmed

Global impact / market context

The case turns on whether Symbicort Turbuhaler 160/4.5 falls under price-controlled drugs, which means official limits on what companies can charge. If it does, AstraZeneca faces a large recovery claim and possible changes to how it prices this inhaler.

Analyst inference

Investors in AstraZeneca Pharma India face uncertainty over a potential cash outflow and over how regulators treat inhaler strengths under price control rules. The interim protection delays any recovery, so the January 11 hearing is the next point that could change the company's cost and revenue outlook.

Analyst inference

What to watch

1. The next hearing is on January 11, when the Delhi High Court is expected to consider the pricing authority's response to AstraZeneca's petition about alleged violations under the 2013 price control order. Confirmed
2. Watch whether the court extends the protection against coercive recovery beyond January 11, or allows the pricing authority to resume action to recover the over 151 crore it claims. Proposed
3. Watch whether the court accepts AstraZeneca's argument that its inhaler strength differs from doses listed for price control, because that decision would shape the company's costs and pricing freedom. Analyst inference

Evidence

• Original source link unavailable